Alessandro A. Viansone, MD

Alessandro A. Viansone, MD, discusses potential future directions for HER2-positive metastatic breast cancer care, including new ADCs and antibodies.

Alessandro A. Viansone, MD, discusses the SATEEN study, ADC-after-ADC sequencing, and maintaining HER2 selective pressure in metastatic breast cancer.

Alessandro A. Viansone, MD, discusses balancing ADCs such as T-DXd against low-toxicity chemotherapy in HER2-positive breast cancer therapy de-escalation.

Alessandro A. Viansone, MD, discusses data that support chemotherapy de-escalation in HER2-positive breast cancer.

Alessandro A. Viansone, MD, notes how the DESTINY-Breast11 trial could support a move away from anthracycline-based therapy in HER2-positive breast cancer.